Esteve, a CataloniaBio & HealthTech member, announced that the Japanese company Towa Pharmaceutical will acquire 100% ownership of its generics division (Pensa Investments). The purchase price of Pensa will be an all cash deal with an upfront payment of 320 million euros.

As part of its strategic plan, Esteve is focusing its business on proprietary products and areas of specialised medicine. 

More information

Photo: Staffan Schüberg, CEO at Esteve - © Esteve